

# Emerging Therapies Workgroup Charter



# I. Background

During the 2019 legislative session, House Bill (HB) 1869 was introduced which would have created an emerging therapies workgroup to analyze prospective and emerging therapies and their impacts on patients in Washington State. The WA Health Care Authority (HCA) appreciates the high level of interest in these new therapies from the medical community and patient groups and has established this workgroup in order to gather important feedback and insight from key stakeholders.

This charter shall expire on June 30, 2020 or when HCA determines that the charter has been fulfilled.

# II. Scope

The Emerging Therapies Workgroup is charged with providing input to HCA on the following topics:

- Long-term funding for emerging treatments.
- Potential funding options between manufacturers and the state, such as value-based purchasing and financing options.
- Different payment options between the state and managed care organizations.
- Quality oversight and outcome tracking of providers and facilities administering the emerging therapies.
- Management of patients eligible for emerging therapies with consideration of the benefit and cost to the overall state budget.
- Potential improvements to health outcomes and quality of life for patients and concerns about safety and efficacy.
- Potential long-term savings or expenditures to the state.
- Metrics that could be used to measure the fiscal and health impacts of emerging therapies.

HCA staff will provide workgroup members materials in advance of scheduled meetings in order to ensure adequate review time and meaningful input.

The workgroup will seek input from other subject matter experts as necessary.

The workgroup will prioritize three to five key immediate action steps based on its analysis and discussion.

The workgroup will make recommendations to HCA leadership. Final decision-making authority resides with HCA.

# III. Schedule

The workgroup will hold four meetings over 12 months between June 1, 2019, and June 30, 2020. The first meeting is June 18<sup>th</sup>, 2019, and will be held in Spokane, Washington. The second meeting will be held on a day to be decided in late October 2019 at HCA in Olympia, 2/19/2020 and 4/15/2020 will be held at the Conference Center at SeaTac Airport.

*Topics to be covered:*

## June 2019 Meeting | LEVEL SETTING

- Overview of new therapies coming to market
- Private sector perspective on managing emerging therapies
- HCA/Medicaid perspective on managing emerging therapies
- Current financing



## October 2019 Meeting | CASE EXAMPLES

- Patient decision aids
- Patient experience
- Patient advocates present

## February 2020 Meeting | FUNDING OPTIONS

- Long-term funding for emerging therapies
- Potential funding options between manufacturers and the state
- Different payment options between the state and managed care organizations

## April 2020 Meeting | QUALITY OVERSIGHT

- Potential improvements and harms to health outcomes and quality of life for patients
- Quality oversight and outcome tracking of providers and facilities administering emerging therapies
- Metrics that could be used to measure the fiscal and health impacts of emerging therapies
- Potential long-term savings and expenditures to the state

## IV. Work Group Membership

Workgroup members will be appointed by HCA and include representatives from various medical fields, along with representatives from managed care organizations and patient advocacy organization.

Chair: Judy Zerzan, MD, MPH – Chief Medical Officer: HCA

## V. Staff Resources

Leta Evaskus – NW Prescription Drug Consortium Operations Manager: HCA

[Leta.Evaskus@hca.wa.gov](mailto:Leta.Evaskus@hca.wa.gov)

206-521-2029

Mike Bonetto – Facilitator: Center for Evidence-based Policy, OHSU

[mbonetto@tenfoldhealth.com](mailto:mbonetto@tenfoldhealth.com)

541-678-3204

